ArticleNPJ Parkinson's disease2026
Metabolic stress exacerbates Parkinson's disease pathology through mitochondrial dysfunction and ferroptosis.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glucose-responsive AMPK-TET2-5hmc oscillation links metabolic stress to circadian transcription and Parkinson's disease relevance.NPJ Parkinson's disease · 2026Article
- Emerging insight in genetics and therapies in young-onset Parkinson's disease (YOPD): a comprehensive review.Journal of neurology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Epidemiological studies have linked type 2 diabetes to Parkinson's disease (PD), but causality and mechanisms remain unclear. Here, using Mendelian randomization, we identify genetically elevated 2‑hour post‑load glucose as a causal risk factor for PD. To investigate the underlying biology, we developed a mouse model combining glucose intolerance with MPTP‑induced dopaminergic injury. Glucose intolerance markedly exacerbated motor and cognitive deficits, dopaminergic neuron loss, and α‑synuclein accumulation. Mechanistically, hyperglycemia synergized with MPTP to impair mitochondrial respiration, collapse membrane potential, and disrupt cristae architecture. These changes were accompanied by iron overload, glutathione depletion, lipid peroxidation, downregulation of the ferroptosis suppressor GPX4, and upregulation of the pro‑ferroptosis enzyme ACSL4-a signature of ferroptosis. The same pathway was activated in human dopaminergic neurons exposed to high glucose and MPP⁺. Our findings establish that glucose intolerance directly aggravates PD pathology via mitochondrial dysfunction and ferroptosis, suggesting that targeting this cell death pathway or improving glycemic control could offer therapeutic opportunities for PD, especially in patients with metabolic comorbidities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.